Evaluate your SaaS company’s scaling readiness and growth bottlenecks against the benchmarks that matter to institutional buyers and growth investors.
Run the DiagnosticSaaS valuation is a direct function of growth efficiency. Two SaaS companies can both report 30% ARR growth and receive dramatically different valuations depending on how that growth was produced. A company buying growth through unsustainable sales headcount and CAC payback periods exceeding 24 months looks fundamentally different than one with expanding NRR, a shortening payback period, and product-led acquisition layered on top of a high-performing sales motion.
The Growth Scaling Diagnostic evaluates your specific unit economics to identify whether your growth trajectory is sustainable — or whether you are running toward a capital call you do not yet see coming.
The most common SaaS scaling problems are pipeline concentration (more than 40% of new ARR from fewer than 3 sourcing channels), sales cycle elongation without corresponding ACV growth, and expansion ARR that is actually disguised churn from customers who churned seats but added users in a different product tier.
The Growth diagnostic benchmarks your expansion rate, pipeline diversity, and sales efficiency against SaaS transaction data to surface the specific bottlenecks that would face scrutiny in a growth equity or M&A diligence process. The output is a ranked list of the constraints limiting your growth multiple — with the highest-impact items at the top.
The diagnostic evaluates unit economics sustainability (CAC payback period, LTV:CAC ratio), pipeline channel diversity, net revenue retention, expansion ARR composition, and go-to-market repeatability. It identifies the specific bottlenecks that would face scrutiny in a growth equity or M&A diligence process.
Net Revenue Retention is one of the primary inputs. The diagnostic distinguishes between genuine expansion from upsell and cross-sell versus re-categorized ARR from product tier changes. It also evaluates the drivers of expansion — whether they are product-led, relationship-driven, or tied to price increases — because each has different sustainability characteristics.
The diagnostic surfaces whether your current growth motion is capital-efficient. Companies with CAC payback periods above 24 months and declining NRR are in a position where additional capital accelerates the problem rather than solving it. The output helps identify whether the priority is operational improvement before a raise, or whether the unit economics support aggressive capital deployment.
AI-generated content · AI Disclaimer